St. John Hospital, Detroit, U.S.
Studies from the United States add new findings to clinical trials body of knowledge
Published in Lab Business Week, July 23rd, 2006
Study 1: Recent trials suggest that additional methods for selecting candidates most likely to benefit from cardiac resynchronization therapy are needed.
Investigators in the United States report, "Based on current patient selection criteria, a significant proportion of recipients of cardiac resynchronization therapy (CRT) do not respond to treatment. The purpose of this analysis is to identify predictors and characterize the timing of response to CRT in patients with advanced heart failure."
"Patients randomized to receive CRT in the MIRACLE and MIRACLE-ICD...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2006-07-23)
More Articles from Lab Business Week
- ATS Medical
ATS Medical intends to amend, restate financial documents - Amorcyte
Amorcyte closes $4.2M series A financing - Array BioPharma
Array BioPharma to get $32 million in cash from facilities transactions - Bridge Pharmaceuticals
Patrik Sebastian Jeanmonod appointed vice president finance of Bridge Pharmaceuticals - Corgentech
Corgentech secures $30 million committed equity financing facility - Epeius Biotechnologies
Epeius Biotechnologies awarded $400,000 grant by Lazarex Cancer Foundation for gene trials - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
